For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

The study found the program was more than 85% effective in reducing infant hospitalizations, emergency-room consultations and ...

The WHO guidance aims to spur development of in vitro diagnostic tests that can quickly and accurately identify serious ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Pregnant individuals commonly reported hesitancy toward RSVpreF and nirsevimab, indicating the need for efforts to promote the safety and uptake of RSV immunization.

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...